Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 20 May 2022, including: a US setback for UCB S.A.; Eli Lilly and Company challenges Novo Nordisk A/S’s GLP franchise; Seagen Inc.  searches for CEO after scandal; Jiangsu Hengrui Medicine Co., Ltd. hopes for US PD-1 success; and a look ahead at ASCO.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx" - Scrip, 13 May, 2022.)

(Also see "Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise" - Scrip, 13 May, 2022.)

(Also see "Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal" - Scrip, 16 May, 2022.)

(Also see "Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing" - Scrip, 16 May, 2022.)

(Also see "Five Late-Breaking Studies To Look Out For At ASCO" - Scrip, 18 May, 2022.)


Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts